
Opinion|Videos|November 20, 2026
Jonathan Rosenberg, MD, reacts to FDA approval of durvalumab plus EV for MIBC
Author(s)Jonathan E. Rosenberg, MD
Fact checked by: Hannah Clarke
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Advertisement
Advertisement
In this video, Jonathan E. Rosenberg, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, discusses the significance of the
Related to this article

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.

Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.

Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.

Faculty weigh the new class-wide blood pressure warning and why dropping the age-related limitation treats low testosterone as a syndrome, not aging.

Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Advertisement
Advertisement

